Despite being hailed as a medical breakthrough, new Alzheimer's drugs may not be the game-changer we hoped for. A comprehensive review reveals that these heavily promoted treatments show surprisingly minimal benefits for patients in real-world scenarios.
Johnson & Johnson's latest clinical data reveals that ICOTYDE, a once-daily pill for plaque psoriasis, is delivering remarkable skin clearance results that last. With nearly 60% of adolescents achieving completely clear skin by week 52, this breakthrough treatment is turning heads in dermatology.
After years of limited progress, tuberculosis research is experiencing a major breakthrough with new vaccines and MDR-TB treatments entering Phase III clinical trials. With TB cases projected to reach 4.5 million across major markets by 2033, these developments could be transformative for global health.
A groundbreaking new analysis reveals a troubling gap in medical research: African populations are dramatically underrepresented in the clinical trials that determine how heart disease is treated worldwide. This absence has serious implications for healthcare equity and patient outcomes across the continent.
After years of relative quiet, tuberculosis research is experiencing a resurgence. Three promising candidates are now in late-stage trials—and they could transform how we fight one of the world's deadliest infectious diseases.
Senhwa Biosciences just unveiled an exciting breakthrough at the 2026 AACR conference—their promising drug CX-5461 is expanding into photodynamic therapy with impressive early results. This strategic pivot could open entirely new therapeutic pathways for cancer patients and reshape how we approach oncology treatment.
For gastrointestinal cancer patients undergoing chemotherapy, low platelet counts can force devastating treatment delays. Now, a promising new therapy offers hope—keeping patients on their critical treatment schedules despite this common complication.